Research Topics
Species | Giovanni D'ArenaSummaryCountry: Italy Publications
| Collaborators
|
Detail Information
Publications
Circulating regulatory T cells in "clinical" monoclonal B-cell lymphocytosisG D'Arena
Department of Onco Hematology, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy
Int J Immunopathol Pharmacol 24:915-23. 2011..In light of this data, MBL seems to be a preliminary phase preceding CLL. The progressive increase of Treg numbers might contribute both to the clinical evolution of MBL to overt CLL and to CLL progression...- Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemiaGiovanni D'Arena
Hematology Oncology Unit, National Cancer Institute, Fondazione G Pascale, Via Mariano Semmola, Naples, Italy
Am J Hematol 82:787-91. 2007.... - Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patientsGiovanni D'Arena
Hematology, Oncology and Bone Marrow Transplantation Unit, National Cancer Institute, Fondazione Pascale, Naples, Italy
Eur J Haematol 79:53-8. 2007..In conclusion, our experience clearly demonstrates that anti-CD20 monoclonal antibody rituximab is an effective and safe alternative treatment option for idiopathic AIHA, in particular, for steroid-refractory disease... - Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemiaGiovanni D'Arena
Hematology and Bone Marrow Transplantation Unit, National Cancer Institute, IRCCS Fondazione G Pascale, Naples, Italy
Am J Hematol 81:598-602. 2006..At a mean follow-up of 17 months, 8 patients were still alive, 6 of them transfusion-free. Our results prove that the anti-CD20 monoclonal antibody is an effective and well-tolerated alternative treatment for CLL-associated AIHA... - Monoclonal antibodies: new therapeutic agents for autoimmune hemolytic anemia?Giovanni D'Arena
Hematology and Stem Cell Transplantation Unit, Scientific Institute, Casa Sollievo della Sofferenza Hospital, 71013 San Giovanni Rotondo, Italy
Endocr Metab Immune Disord Drug Targets 8:62-8. 2008.... - Rituximab to treat chronic lymphoproliferative disorder-associated pure red cell aplasiaGiovanni D'Arena
Hematology and Stem Cell Transplantation Unit, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
Eur J Haematol 82:235-9. 2009..Despite very limited in number, these results suggest that rituximab is very effective in the treatment of PRCA complicating B-cell chronic lymphoproliferative disorders... - Guillain-Barré syndrome complicating mobilization therapy in a case of B-cell chronic lymphocytic leukemiaGiovanni D'Arena
Department of Internal Medicine, S Luca Hospital, Vallo della Lucania SA, Italy
Leuk Lymphoma 45:1489-90. 2004..It is possible that a viral-induced activation of an antigen-specific T and B-cell clone caused a local inflammation and toxicity of Schwann cells with demyelination and axonal damage with a self-limited course... - Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patientsGiovanni D'Arena
Hematology and Stem Cell Transplantation Unit, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
Eur J Haematol 85:502-7. 2010..There are no standard therapies for chronic lymphocytic leukemia (CLL)-associated immune thrombocytopenia (IT) so far... - Chronic lymphocytic leukemia-associated autoimmune hemolytic anemiaGiovanni D'Arena
Hematology Oncology and Bone Marrow Transplantation Unit, National Cancer Institute, IRCCS Fondazione G Pascale, Naples, Italy
Leuk Lymphoma 48:1072-80. 2007..Furthermore, although the case series is still too small, encouraging data is now supporting the use of monoclonal antibodies, in particular anti-CD20 rituximab, in managing this often life-threatening autoimmune complication of CLL... - Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive diseaseGiovanni D'Arena
IRCCS Casa Sollievo della Sofferenza Hospital, 71013 San Giovanni Rotondo, Italy
Leuk Res 35:363-8. 2011..No correlation was found with ZAP-70 expression, IgVH mutational status and cytogenetic abnormalities. This data shows that Treg cell number is abnormal in CLL patients... - Targeting regulatory T cells for anticancer therapyG D'Arena
Hematology and Stem Cell Transplantation Unit, IRCCS Casa Sollievo della Sofferenza Hospital, Viale dei Cappuccini n 1, 71013 San Giovanni Rotondo FG, Italy
Mini Rev Med Chem 11:480-5. 2011..This could lead to restore antitumor immunity and emerging strategies for therapeutic vaccination, and immunotherapeutic targeting of Tregs with specific drugs are underway... - Usefulness of RA and RO isoforms of common leukocyte antigen (CD45) for early distinction between normal and abnormal promyelocytesGiovanni D'Arena
Department of Onco Hematology, San Giovanni di Dio e Ruggi d Aragona Hospital, 84100 Salerno, Italy
Leuk Lymphoma 43:1823-5. 2002.... - Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targetsGiovanni Rossi
Department of Hematology and Stem Cell Unit, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
Leuk Res 36:401-6. 2012..Therefore, MFC and WT1-RNA quantification showed a comparable capacity in terms of technical performance and clinical significance to identify high risk patients who eventually relapsed... - Is the scoring system an effective clinico-biological tool in myeloid antigen positive adult acute lymphoblastic leukemia? Results of a long-term studyNicola Cascavilla
Department of Hematology and Bone Marrow Transplantation, Casa Sollievo della Sofferenza Hospital, IRCCS 71013, San Giovanni Rotondo, Italy
Hematol J 3:251-8. 2002..The classification and the clinical management of adult acute lymphoblastic leukemias (ALL) that co-express myeloid antigens (MyALL) remain controversial because of the confusion of terms and criteria to define these cases... - Biological and clinical heterogeneity of B-cell chronic lymphocytic leukemiaGiovanni D'Arena
Hematology and Oncology Unit, C R O B Regional Hospital, Rionero in Vulture, Italy
Leuk Lymphoma 44:223-8. 2003..Thus, the definition of the biological features of these different groups could be of help for clinicians in order to recognize patients needing more intensive therapeutic approaches... - Non-pegylated liposomal doxorubicin (Myocet®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphomaMatteo Dell'Olio
Hematology Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy
Leuk Lymphoma 52:1222-9. 2011..6?±?6.9% to 54.2?±?3.9%). Grade 3-4 neutropenia occurred in 22% of patients. We concluded that Myocet® shows both efficacy and tolerability, mainly at the cardiac level... - Collection of peripheral progenitor cells: a comparison between Amicus and Cobe-Spectra blood cell separatorsGaspare Adorno
Department of Immunohematology, Tor Vergata University of Rome, Viale Oxford, 81, 00133 Rome, Italy
Transfus Apher Sci 30:131-6. 2004..0) and Amicus separators have the same efficiency for collecting CD34+ cells while Amicus procedures have a very low platelet contamination, especially with donors... - Comparison between conventional banding analysis and FISH screening with an AML-specific set of probes in 260 patientsMaria Christina Cox
Department of Hematology, University Tor Vergata, St Eugenio Hospital, Rome, Italy
Hematol J 4:263-70. 2003..Furthermore, we suggest FISH screening in failed, complex or suboptimal quality chromosome and specific FISH analysis for 5q, 7q, 12p, 17p, inv(16), t(11q23) in order to implement CBA accuracy... - Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized studyGiovanni D'Arena
Hematology and Stem Cell Transplantation Unit, IRCCS Casa Sollievo della Sofferenza Hospital, S Giovanni Rotondo, Italy
Leuk Lymphoma 52:771-5. 2011..009). In conclusion, the administration of pamidronate in asymptomatic myeloma, while reducing bone involvement at progression, did not decrease the risk of transformation and the time to progression into overt myeloma... - Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemiaLuca Maurillo
Hematology, Policlinico Tor Vergata and Ospedale S Eugenio, Rome, Italy
J Clin Oncol 26:4944-51. 2008..The effects of autologous (AuSCT) or allogeneic stem-cell transplantation (SCT) are still under evaluation. Minimal residual disease (MRD) states may be essential for assigning patients to therapy-dependent risk categories... - Immunophenotypic profile of AC133-positive cells in bone marrow, mobilized peripheral blood and umbilical cord bloodGiovanni D'Arena
Department of Onco Hematology, San Giovanni di Dio e Ruggi d Aragona Hospital, Salerno, Italy
Leuk Lymphoma 43:869-73. 2002.... - Familial B-cell chronic lymphocytic leukemia in a population of patients from Southern ItalySilvana Capalbo
Hematology, University of Bari, Policlinico, Bari, Italy
Int J Hematol 79:354-7. 2004..CLL was the most frequent disease in relatives, mainly siblings, of our CLL patients. Our results may be a contribution to the characterization of the epidemiological distribution pattern of CLL... - GIMEMA ALL - Rescue 97: a salvage strategy for primary refractory or relapsed adult acute lymphoblastic leukemiaAndrea Camera
Hematology, Federico II University, Naples, Italy
Haematologica 89:145-53. 2004..However, significant rates of transplant-related mortality and post-transplant relapse encourage the search for more effective and less toxic conditioning regimens... - Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trialPellegrino Musto
Unit of Hematology and Stem Cell Transplantation, IRCCS Casa Sollievo della Sofferenza Hospital, 71013, S Giovanni Rotondo, Italy
Leuk Lymphoma 44:1545-8. 2003..01). "Prophylactic" administration of PMD may decrease the development of skeletal events, but does not reduce the rate and the time of disease progression in early-stage myeloma... - Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomidePellegrino Musto
Unit of Hematology and Stem Cell Transplantation, IRCCS Casa Sollievo della Sofferenza Hospital, S Giovanni Rotondo, Italy
Leuk Res 30:283-5. 2006.... - Role of parenteral nutrition in cancer patients undergoing high-dose chemotherapy followed by autologous peripheral blood progenitor cell transplantationAlfredo Tartarone
Division of Medical Oncology and Hematology, Centro di Riferimento Oncologico della Basilicata CROB, Rionero in Vulture PZ, Italy
Tumori 91:237-40. 2005..Nevertheless, well-defined guidelines for its use in this clinical setting are lacking and there are several areas of controversy... - Cisplatin and weekly docetaxel as first-line therapy in patients with advanced non-small cell lung cancer a phase II studyAlfredo Tartarone
Division of Medical Oncology and Hematology, Centro di Riferimento Oncologico della Basilicata CROB, Rionero in Vulture PZ, Italy
Tumori 91:131-4. 2005..Based on the results of previous phase I studies, in the current phase II trial we evaluated the efficacy and toxicity of cisplatin plus weekly docetaxel in the treatment of advanced non-small cell lung cancer (NSCLC)... - High-dose chemotherapy for breast cancerAlfredo Tartarone
N Engl J Med 349:1476-9; author reply 1476-9. 2003 - Quantitative evaluation of CD52 expression in B-cell chronic lymphocytic leukemiaMaria Luigia Vigliotti
Leuk Lymphoma 44:1255-7. 2003 - Late and long-lasting response in an adult chronic idiopathic thrombocytopenic purpura after extended course of rituximabMaria Luigiavigliotti
Leuk Lymphoma 44:561-2. 2003